irinotecan fresenius concentrate for solution for infusion 20mg - Výsledky vyhľadávania

Malta - angličtina - Medicines Authority

irinotecan hydrochloride concentrate for soln for inf 20mg/ml (5ml)

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents

Malta - angličtina - Medicines Authority

irinotecan hydrochloride concentrate for soln for inf 20mg/ml (25ml)

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Malta - angličtina - Medicines Authority

irinotecan ebewe - (2ml vial) concentrate for soln for inf 20mg/ml